Sponsored satellite symposia
Daiichi Sankyo/AstraZeneca sponsored satellite symposium
A team approach to the treatment of patients with HER2-postive metastatic breast cancer
On-demand session (duration: 01h15): |
|
Welcome and meeting objectives |
|
A patient in your clinical practice |
|
My patient with HER2-positive metastatic breast cancer: What are my current treatment options? |
|
Adverse event awareness and management: Optimising patient outcomes |
|
My patient with HER2-positive metastatic breast cancer: What possibilities might there be in the future? |
|
Panel discussion |
|
Live Q&A: Friday 5 November 2021 17:30-17:45 |
|
Véronique Diéras, FR - Rupert Bartsch, AT - Andreas Charalambous, CY |
|
Symposium faculty |
Lilly sponsored satellite symposium
Beyond the doors of MDT meeting: impact on HR+HER2- breast cancer patients. Real world discussion
On-demand session (duration: 01h00): |
|
Welcome and introduction |
|
Clinical case discussion: high risk ER+/HER2- early breast cancer |
|
Clinical case discussion: de novo metastatic disease |
|
Take home messages |
|
Symposium faculty |
Novartis sponsored satellite symposium
What matters to patients with HR+ HER2– ABC: Expanding options for living better for longer
On-demand session (duration: 01h30): |
|
Opening remarks |
|
CDK4/6 inhibitors in HR+ HER2– ABC: Maximizing impact on overall survival and quality of life |
|
Discussion |
|
Personalizing treatment to ensure optimal benefit from PI3K inhibitors in HR+ HER2– ABC |
|
Discussion |
|
Closing remarks |
|
Symposium faculty |
Pfizer sponsored satellite symposium
Raising awareness of underserved patient populations: Solutions from the real world
On-demand session (duration: 45min): |
|
Welcome and introduction to underserved populations |
|
Managing underserved patients in the real-world |
|
Live Q&A: Saturday 6 November 2021 13:30-13:45 |
|
Symposium faculty |
Seagen sponsored satellite symposium
Multidisciplinary team perspectives on the evolving treatment landscape in HER2+ MBC
On-demand session (duration: 45 min): |
|
Introduction to the session - Filippo Montemurro, IT (Chair) |
|
Welcoming our patient: What are the considerations for her management? |
|
The disease of our patient progresses: How could emerging treatment options support her journey? |
|
Our patient experiences brain metastases: What are her options? |
|
Icro Meattini, IT - Filippo Montemurro, IT - Doris Schmitt, DE |
|
Live Q&A: Friday 5 November 2021 13:30-13:45 |
|
Icro Meattini, IT - Filippo Montemurro, IT - Doris Schmitt, DE |
|
Symposium faculty |